The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that s...
Source: [SCMP](https://www.scmp.com/news/china/science/article/3362253/chinas-biotech-boom-risk-fear-policy-backlash-after-death-gene-editing-trial?utm_source=rss_feed)